Drug intelligence / Profile preview

BL-122

Development stage: Preclinical
Lead developer: Biolab Farmacêutica
Modality: Small Molecules

Overview

BL-122 is an experimental small molecule drug candidate being developed by the Brazilian pharmaceutical company Biolab Pharma (Biolab Sanus Farmacêutica). It is identified in pipeline databases as a phosphodiesterase 5A (PDE5A) inhibitor. Uniquely, the primary indication associated with this compound is mycoses (fungal infections), suggesting a potential application of PDE5 inhibition in antifungal therapy or a specific role in modulating fungal signaling pathways. As of current reports, the drug is in the early stages of development with its clinical status listed as pending.

Targets

PDE5 (Phosphodiesterase 5A)

Beyond the preview

Go deeper on BL-122.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BL-122.

Explore the full profile